Herein, we present the case of a 55-year-old patient who developed a severe zoster reaction after receiving the AstraZeneca COVID-19 vaccine. Although zoster reactivation has already been observed with various vaccines, the extent and length of this reaction raise serious concerns. Hopefully, the outcome of this patient was favorable. The case of this patient, who could have only received a single dose of the vaccine, suggests that immunity after this type of vaccine vanishes rapidly and booster shots will be of crucial importance in the future.

This observational real-world study was conducted on 14 patients who needed a minor office surgery or procedure and who were eligible for a COVID-19 booster according to the French Health Agency. The aim of the study was focused on biological markers which might have an incidence after surgery. The platelet count, D-dimer level, and anti-spike IgG antibodies levels, were the numeric parameters studied. The study showed no perturbation in the platelet count. Conversely, we observed an abnormal elevation of D-dimer levels in 4 patients (28 %). The most remarkable data was the constant residual positive level anti-spike IgG antibodies observed in all patients after 6 months ranging from 44 to 5680 BAU/mL. For these reasons, further studies on a bigger cohort would be useful to clarify the possible incidence of COVID-19 vaccines on D-dimer levels and a monitoring of the immune response should be proposed to all patients eligible for a SARS-CoV-2 vaccine booster in order to evaluate the benefit-risk ratio of this injection.